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progression was 5.0 months (95%CI: 1.8-8.1). In 22 patients 
with pain, a significant reduction of this symptom was 
recorded in terms of VAS (mean baseline VAS vs mean VAS at 
follow-up: 4.6 versus 3.1, p<0.001).  
 
Conclusion: Short-course accelerated H&N radiotherapy (20 
Gy in twice daily fractions for 2 consecutive days) is 
tolerated and effective in terms of symptom relief. A phase 
III comparison against a standard palliative regimen (30 Gy in 
10 fractions) has been planned in this patient population. 
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Purpose or Objective: To assess the effectiveness of a SHort-
course Accelerated RadiatiON therapy (SHARON) in the 
palliative treatment of patients with primary or secondary 
thoracic neoplasms, symptomatic, and not susceptible of 
surgery or radical radiotherapy. 
 
Material and Methods: A phase II clinical trial was planned 
based on optimal two-stage Simon’s design. Eligibility criteria 
included patients with an Eastern Cooperative Oncology 
Group (ECOG) performance status of ≤3 and an expected 
survival > 3 months. Twenty-five patients were treated with 
radiotherapy (total dose: 20 Gy, 5 Gy per fraction) in 2 days 
with twice daily fractionation. The primary endpoint was to 
evaluate symptoms response rate. 
 
Results: Characteristics of the 25 enrolled patients were: 
male/female: 18/7; median age: 73 years (range: 46-93). 
ECOG performance status was <3 in 24 patients (96%). Two 
G1 skin (8%), 7 G1 haematological (28%) and 4 G1 pulmonary 
(16%) toxicities were recorded. No patient experienced G≥2 
acute toxicities. With a median follow-up time of 6 months 
(range, 1 to 16 months), of the 25 symptomatic patients, 24 
showed an improvement or resolution of baseline symptoms 
(overall palliative response rate: 96%). Three months overall 
survival was 87.5% (median survival time: 6 months; 95% CI 
5.3-6.6 mo). Median survival without symptoms progression 
was 3 months (95% CI:2.2-3.7mo). In 24 patients with pain, a 
significant reduction of this symptom was recorded in terms 
of VAS (5.0 vs 2.9, p=0.02). 
 
Conclusion: Short-course accelerated thorax radiotherapy 
(20 Gy in twice daily fractions, 2 consecutive days) is 
tolerated and effective in terms of symptom relief. A phase 
III comparison against a standard palliative regimen (30 Gy in 
10 fractions) has been planned in this patient population. 
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Purpose or Objective: Modern technologies of radiotherapy 
(SBRT,SABR) are utilized to treat patients with solitary spine 
metastases. Clinical studies have shown the efficacy of 
image-guided SBRT for pain control, local tumor control, as 
well as improvement of the life`s quality for these patients. 
In our clinic we have been using this method since 2013 for 
primary and re-irradiation treatment. 
 
Material and Methods: We have treated 32 pts (20 primary, 
12 reirradiation), 44 lesions. Eligible criteria were ECOG 1-2, 
spine metastases confirmed by MRI, the number of lesions 
were less than 3, adequate control of the primary tumor. 
Mean age 55.8 y.o. (47-72); gender distribution: 12 men and 
20 women. Option of the radiation dose and limit critical 
organs were installed according to the recommendations 
Elekta Spine Radiosurgery Research Consortium (ESRRC) and 
RTOG 0631. The prescribed dose was 12-24 Gy in 1-3 fr. For 
re-irradiation we have used the recommendations of Nieder 
et al.(2006): BED of each course - 98Gy, total BED -135.5Gy, 
the interval between two treatments was more than 6 
months. In these cases the prescribed dose was 20Gy in 5 fr. 
The procedure was performed by VMAT on a linear 
accelerator Elekta Synergy S, equipped with a 4-mm MLC, 
image-guided system (Elekta XVI), 6D robotic positioning 
system table (HexaPod). Overall duration of procedures was 
20-45 min. The follow-up was every 3 months from treatment 
time. It was assessed the pain intensity on a 10-point VAS, 
analgesics, performed MRI control. 
 
Results: Toxicity of SBRT was assessed by using CTC AE 
(v.4.0). Nausea gr.1 was observed in 3 (9.4%) pts, vomiting 
gr.1 - 1 (3.1%) pt. Toxicity gr.3-4 has not been observed. 
There were no cases of therapy interruption due to poor 
tolerability. Hematological toxicity during follow-up period 
was not revealed. In average of the period of 3 weeks all 
patients showed relief of pain syndrome with moderate (4-6 
points) to the minimum (1-3 points). The overall response to 
treatment (decrease of pain syndrome, local tumor control 
by MRI) was 90.6%, including a complete pain relief - 8 (25%) 
pts, stabilization - 21 (65.6%), lack of response to the 
treatment- 3 (9,4%). One patient had a pathological 
compression fracture of the vertebra at 4 months after 
irradiation, which required surgical intervention (installation 
of the fixing system). According to one patient`s MRI after 3 
month of treatment, we have revealed soft tissue component 
of tumor (MRI). 
 
Conclusion: SBRT was well tolerated. We did not observe any 
clinically significant toxicity. Reduction of the overall 
treatment time was comfortable for patients and increase 
capacity of LINAC. Further research is necessary to evaluate 
the efficacy and toxicity of the treatment and the 
development of criteria for the selection of patients. 
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